Penicillin-Susceptible Streptococcus pneumoniae Meningitis in Adults: Does the Ceftriaxone Dosing Matter?

The recommended empiric ceftriaxone dosing regimen for acute bacterial meningitis in adults is 2 g every 12 h. After penicillin-susceptible Streptococcus pneumoniae is isolated as a causative microorganism, the ceftriaxone dose may be continued or reduced to a single dose of 2 g every 24 h, per institutional preference. There is no clear guidance that indicates the superiority of one regimen over the other. The objective of this study was to evaluate the susceptibility of S. pneumoniae in the cerebral spinal fluid (CSF) of patients with meningitis and the relationship between ceftriaxone dose and clinical outcomes. We identified 52 patients with S. pneumoniae meningitis with positive CSF cultures who were treated at the University Hospital, Bern, Switzerland, over a 19-year period. We collected clinical and microbiological data for evaluation. Broth microdilution and Etest methods were performed to test penicillin and ceftriaxone susceptibility. All isolates were susceptible to ceftriaxone. Ceftriaxone was empirically used in 50 patients, with a starting dosing regimen of 2 g every 24 h in 15 patients and 2 g every 12 h in 35 patients. In 32 patients started on a twice-daily regimen (91%), doses were reduced to once daily after a median of 1.5 (95% CI 1–2) days. The overall in-hospital mortality was 15.4% (n = 8), and 45.7% of patients reported at least one sequela of meningitis at the last follow-up (median 375, 95% CI 189–1585 days). We found no statistical difference in outcome between the 2 g every 24 h and the 2 g every 12 h ceftriaxone dosing regimens. A ceftriaxone total daily dose of 2 g may be associated with similar outcomes to a 4 g total daily dose, provided that the causative organism is highly susceptible to ceftriaxone. The persistence of neurological and infection sequelae at the last follow-up underscores the need for optimal treatment of these complex infections.

[1]  G. Joynt,et al.  Multicenter Population Pharmacokinetic Study of Unbound Ceftriaxone in Critically Ill Patients , 2022, Antimicrobial agents and chemotherapy.

[2]  D. Marriott,et al.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# , 2020, Intensive Care Medicine.

[3]  V. Sébille,et al.  High-Dose Ceftriaxone for Bacterial Meningitis and Optimization of Administration Scheme Based on Nomogram , 2019, Antimicrobial Agents and Chemotherapy.

[4]  D. Boutoille,et al.  CSF concentration of ceftriaxone following high-dose administration: pharmacological data from two French cohorts. , 2019, The Journal of antimicrobial chemotherapy.

[5]  R. Heyderman,et al.  Acute bacterial meningitis in adults , 2016, The Lancet.

[6]  C. Whitney,et al.  Community-acquired bacterial meningitis , 2016, Nature Reviews Disease Primers.

[7]  K. Mühlemann,et al.  Serotype/serogroup-specific antibiotic non-susceptibility of invasive and non-invasive Streptococcus pneumoniae, Switzerland, 2004 to 2014. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  B. Mourvillier,et al.  ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  B. Salzberger,et al.  Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. , 2015, British journal of clinical pharmacology.

[10]  A. van der Ende,et al.  Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data. , 2014, The Lancet. Infectious diseases.

[11]  S. Rulisa,et al.  A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis. , 2013, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[12]  Diederik van de Beek,et al.  Pathogenesis and Pathophysiology of Pneumococcal Meningitis , 2011, Clinical Microbiology Reviews.

[13]  F. Sörgel,et al.  Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections , 2010, Clinical Microbiology Reviews.

[14]  V. Buchta,et al.  [Penetration of ceftriaxone into the cerebrospinal fluid and its relationship to inflammatory markers during bacterial meningitis]. , 2010, Klinicka mikrobiologie a infekcni lekarstvi.

[15]  O. Sipahi,et al.  Pooled Analysis of 2,408 Cases of Acute Adult Purulent Meningitis from Turkey , 2007, Medical Principles and Practice.

[16]  Ronald N. Jones,et al.  Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. , 2007, Diagnostic microbiology and infectious disease.

[17]  Wouter A Dreschler,et al.  Dexamethasone and long‐term outcome in adults with bacterial meningitis , 2006, Annals of neurology.

[18]  T. Poll,et al.  Pneumococcal meningitis in adults: new approaches to management and prevention , 2006, The Lancet Neurology.

[19]  J. Reitsma,et al.  Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series , 2006, The Lancet Neurology.

[20]  Martijn Weisfelt,et al.  Clinical features and prognostic factors in adults with bacterial meningitis. , 2004, The New England journal of medicine.

[21]  H. Pfister,et al.  Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. , 2003, Brain : a journal of neurology.

[22]  C. Çavuşoğlu,et al.  Does dexamethasone affect ceftriazone penetration into cerebrospinal fluid in adult bacterial meningitis , 2003 .

[23]  H. Pfister,et al.  Pathogenesis and pathophysiology of pneumococcal meningitis. , 2002, The Lancet. Infectious diseases.

[24]  B. Schmand,et al.  Cognitive impairment in adults with good recovery after bacterial meningitis. , 2002, The Journal of infectious diseases.

[25]  I. Lutsar,et al.  Pharmacokinetics and Pharmacodynamics of Cephalosporins in Cerebrospinal Fluid , 2000, Clinical pharmacokinetics.

[26]  C. Cabellos,et al.  A single daily dose of ceftriaxone for bacterial meningitis in adults: experience with 84 patients and review of the literature. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  I. Bekersky,et al.  Plasma protein binding of ceftriaxone. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.

[28]  R. Spector Ceftriaxone pharmacokinetics in the central nervous system. , 1986, The Journal of pharmacology and experimental therapeutics.

[29]  J. Lefrock,et al.  Diffusion of ceftriaxone into the cerebrospinal fluid of adults. , 1984, The Journal of antimicrobial chemotherapy.

[30]  Jonathan,et al.  Pharmacokinetic characteristics of intravenous ceftriaxone in normal adults , 1982, Antimicrobial Agents and Chemotherapy.

[31]  Jerome J. Schentag,et al.  Clinical Use of Ceftriaxone , 2001, Clinical pharmacokinetics.